Hodgkin Lymphoma
News
Drug produces ‘dramatic’ results in HL
The anti-CD30 antibody-drug conjugate brentuximab vedotin can prolong progression-free survival (PFS) in Hodgkin lymphoma (HL) patients who have...
News
Brentuximab doubles PFS in Hodgkin’s lymphoma patients
News
New radiation guidelines for pediatric HL
New guidelines on radiation therapy aim to help physicians more effectively treat pediatric Hodgkin lymphoma (HL) while reducing the radiation...
News
Cancer care spending doesn’t correlate to lives saved
Photo by Rhoda Baer A new analysis suggests that although US spending on cancer treatment has increased greatly in recent years, cancer mortality...
News
Why EBV-positive lymphomas resist IFN therapy
Credit: Ed Uthman New research has revealed how Epstein Barr virus (EBV) and other herpes viruses outwit the body’s immune response. It seems...
Conference Coverage
HIV doesn’t hinder lymphoma patients’ response to ASCT
a cultured lymphocyte Credit: CDC SAN FRANCISCO—Patients with HIV-related lymphoma (HRL) should not be excluded from clinical trials of...
Conference Coverage
Older patients benefit from brentuximab treatment
Credit: NIH SAN FRANCISCO—Younger patients with Hodgkin lymphoma fare well on brentuximab vedotin, experiencing an overall objective response...
Conference Coverage
Classic HL vulnerable to PD-1 blockade therapy
SAN FRANCISCO—Two monoclonal antibodies that block the programmed death-1 (PD-1) pathway are showing promise in early phase trials in relapsed/...
Conference Coverage
Brentuximab combinations highly active in Hodgkin lymphoma
Photo courtesy of ASH SAN FRANCISCO—Two recent studies have shown combination therapy with brentuximab vedotin to be highly active in newly...
Conference Coverage
PFS improvement will translate to OS, speaker says
The overall survival (OS) data for this study are not yet mature, but the significant improvement in PFS will likely translate to improved OS in a...
Conference Coverage
Brentuximab changes landscape for post-transplant Hodgkin’s lymphoma patients
Key clinical point: Brentuximab vedotin given immediately post-transplant significantly improves progression-free survival in patients with...